CRDF Overview
Upcoming Projects (CRDF)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (CRDF)
-
Looking at Cardiff Oncology's Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC)
Ticker: CRDF
Executed On: Jan 10, 2025 at 08:05 AM EST -
Discussing investigational therapies in CRC, including DKN-01+bevacizumab+chemo (triple combo) in 2nd line from Leap Therapeutics and onvansertib, a PLK1 inhibitor in 1st and 2nd line from Cardiff Oncology.
Tickers: CRDF, LPTX
Executed On: Apr 30, 2024 at 10:30 AM EDT
Expired Projects (CRDF)
-
Investigating Cardiff Oncology's Onvansertib as a therapy for pancreatic cancer
Ticker: CRDF
Execute By: Oct 27, 2023 -
Discussing Cardiff Oncology’s onvansertib in KRAS-mutated Metastatic Colorectal Cancer
Ticker: CRDF
Execute By: Apr 30, 2022
Upcoming & Overdue Catalysts (CRDF)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (CRDF)
Strategic Initiatives (CRDF)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
